Which vaccine is recommended for reducing the risk of genital warts in individuals aged 9 to 26 years?

Study for the APhA Immunization Exam. Prepare with flashcards and multiple choice questions, each with hints and explanations. Get ready for your certification!

The vaccine recommended for reducing the risk of genital warts in individuals aged 9 to 26 years is the 9-valent human papillomavirus (9vHPV) vaccine. This vaccine targets nine strains of HPV, including the two strains (HPV types 6 and 11) that are most commonly associated with genital warts. By providing protection against these specific strains, the 9vHPV vaccine significantly reduces the incidence of genital warts, as well as various HPV-related cancers, such as cervical and other genital cancers.

While the 4-valent HPV vaccine (4vHPV) also covers HPV types 6 and 11 and protects against genital warts, the 9vHPV offers broader protection by including additional HPV types that are associated with both cancers and warts. The 2-valent HPV vaccine (2vHPV) covers only two types (HPV 16 and 18), which primarily contribute to cervical cancer, but does not provide protection against the types that cause genital warts. Tdap is a vaccine for tetanus, diphtheria, and pertussis, and is not related to HPV vaccination.

Subscribe

Get the latest from Examzify

You can unsubscribe at any time. Read our privacy policy